Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

(2011) Catherine Liu et al.   CLINICAL INFECTIOUS DISEASES

Staphylococcus aureus Panton-Valentine Leukocidin Is a Very Potent Cytotoxic Factor for Human Neutrophils

(2010) Bettina Löffler et al.   PLoS Pathogens

Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia

(2009) Y. Harigaya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Paradoxical Relationship between the Clinical Outcome ofStaphylococcus aureusBacteremia and the Minimum Inhibitory Concentration of Vancomycin

(2009) James Price et al.   CLINICAL INFECTIOUS DISEASES

Relationship between Initial Vancomycin Concentration‐Time Profile and Nephrotoxicity among Hospitalized Patients

(2009) Thomas P. Lodise et al.   CLINICAL INFECTIOUS DISEASES

Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density

(2009) Brian T. Tsuji et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore

(2009) R. K. C. Fong et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections

(2009) Elizabeth D Hermsen et al.   Expert Opinion On Drug Safety

Vancomycin MIC plus Heteroresistance and Outcome of Methicillin-Resistant Staphylococcus aureus Bacteremia: Trends over 11 Years

(2009) A. C. Musta et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Reduced Susceptibility to Vancomycin Influences Pathogenicity inStaphylococcus aureusInfection

(2009) Anton Y. Peleg et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical Features of Heteroresistant Vancomycin-IntermediateStaphylococcus aureusBacteremia versus Those of Methicillin-ResistantS. aureusBacteremia

(2009) Yasmin Maor et al.   JOURNAL OF INFECTIOUS DISEASES

Is High Vancomycin Minimum Inhibitory Concentration a Good Marker to Predict the Outcome of Methicillin‐ResistantStaphylococcus aureusBacteremia?

(2009) Antonio Lalueza et al.   JOURNAL OF INFECTIOUS DISEASES

Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

(2008) M. Rybak et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin

(2008) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increasing Antibiotic Resistance among Methicillin‐ResistantStaphylococcus aureusStrains

(2008) George Sakoulas et al.   CLINICAL INFECTIOUS DISEASES

Associations between the Genotypes of Staphylococcus aureus Bloodstream Isolates and Clinical Characteristics and Outcomes of Bacteremic Patients

(2008) T. Lalani et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

(2007) A. Soriano et al.   CLINICAL INFECTIOUS DISEASES